Business Wire

Mentice: New Research Concludes Metric-based Simulation Helps Improve How Physicians Learn Mechanical Thrombectomy

Del

Mentice welcomes the publication of a research paper in the journal “Stroke” based on the use of its VIST® physics-based, high-fidelity simulator to train interventional neuroradiologists (INRs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180611005425/en/

Left to right: Anthony G. Gallagher, PhD, DSc; Thomas Liebig, MD, PhD; Markus Holtmannspötter, MD; R ...

Left to right: Anthony G. Gallagher, PhD, DSc; Thomas Liebig, MD, PhD; Markus Holtmannspötter, MD; Robert Crossley, MRCS; Johan Lindkvist, MSc; Lars Lönn, MD. (Photo: Business Wire)

The paper, Metric-Based Virtual Reality Simulation for Mechanical Thrombectomy—A Paradigm Shift in Training for Mechanical Thrombectomy in Acute Stroke, researched the use of high-end virtual reality simulation for the acquisition of skills for this minimally invasive procedure.

Mechanical thrombectomy is a life-saving procedure in which a clinical device is introduced into the affected brain’s vasculature to mechanically remove a blood clot. With several significant studies published during 2015, mechanical thrombectomy has been established as the most effective and preferable solution for ischemic stroke. Despite this, initial acquisition of skills for new operators as well as maintenance of skills for lower volume operators and centers are factors that limit the access for patients to safely receive this novel treatment.

Funded by a grant from the Swedish innovation agency VINNOVA, Mentice has worked with a group of senior INRs and the ASSERT Center at University College Cork to develop and validate a simulation-based training system that can objectively, consistently, and reliably quantify the performance levels of physicians wishing to become proficient in mechanical thrombectomy.

The system uses metrics derived from experienced INRs to establish a level of proficiency, i.e. a performance benchmark, that physicians must reach before performing on real patients. This offers a standardized and quality assured approach to acquire, maintain and assess the endovascular skills needed for this procedure.

“Providing timely and high-quality treatment for ischemic stroke,” says Mentice CEO Göran Malmberg, “is one of today’s largest healthcare opportunities. High-fidelity simulation combined with proficiency-based progression is a disruptive solution that can help this transformation of healthcare.”

This solution is created with the purpose of assisting in a safe and effective roll-out and expansion of the treatment of ischemic stroke using mechanical thrombectomy. The paper concludes that metric-based simulation training can supplant a significant part of the learning curve on real patients and serves as a powerful tool to reproducibly augment the practical skills of endovascular procedures.

“Mechanical Thrombectomy for acute stroke,” says Professor Tony Gallagher of ASSERT, “is a life-changing treatment for many acutely ill patients. The success of the treatment is determined in no small part by the skills of the physician performing the procedure. The VR simulation that we describe, and the training methodology will be used to enhance, and quality assure the learning experience and training of doctors. Conceptually and intellectually appealing, it represents a paradigm shift in how doctors are prepared for the treatment of acute stroke.”

About Mentice

Mentice is the world leader in virtual reality‐based interventional medical simulation solutions. Our solutions help healthcare professionals with skills acquisition, continuous development and preprocedural planning—leading to improved productivity and outcomes. Mentice solutions are scientifically validated, and have been specifically developed for healthcare providers and the medical industry. Neurovascular, cardiovascular and peripheral interventions are just some of the areas covered by our systems. Learn more about the features and benefits of Mentice solutions at: www.mentice.com.

Contact information

Mentice
Hiral Chavda, +46 31 339 94 00
hiral.chavda@mentice.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00Pressemelding

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05Pressemelding

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40Pressemelding

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37Pressemelding

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43Pressemelding

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovation15.8.2018 17:05Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has been honored with a Stevie® Award in the Innovation in Customer Service Management, Planning & Practice category for its ultra-responsive, premium level service in the Asia-Pacific region. This honor marks the Company’s 12th Stevie Award win this year, and the second consecutive year the Company has been recognized by the Asia-Pacific Stevie Awards. Rimini Street recently earned Stevie Awards in several categories, including Company of the Year from the 2018 American Business Awards® and Customer Service Department of the Year from the 2018 Stevie Awards for Sales & Customer Service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005580/en/ Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovat